Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer Journal Article
| Authors: | Kelly, W. K.; Curley, T.; Leibertz, C.; Dnistrian, A.; Schwartz, M.; Scher, H. I. |
| Article Title: | Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer |
| Abstract: | Purpose: To assess efficacy of intermittent infusion of suramin in patients with androgen-independent prostate cancer who have had disease progression on hydrocortisone. Patients and Methods: Chemotherapy-naive patients with progressive androgen-independent prostate cancer were given hydrocortisone 40 mg/d and monitored for treatment effect. At the time of disease progression, suramin was administered on a pharmacokinetically derived, 2-week dosing schedule. Results: Thirty patients with a median Karnofsky performance status (KPS) of 90% were treated with hydrocortisone. No responses were seen in 12 patients with measurable disease or 29 patients with abnormal bone scans. Thirty patients had an increasing prostate-specific antigen (PSA) level before treatment and six (20%) had a more than 50% decline in PSA from the baseline value for a median of 16 weeks (range, 12 to 52+). Twenty-eight patients had disease progression after a median of 7 weeks (range, 3 to 23), and two patients have continued to receive hydrocortisone for 44 and 52 weeks. Twenty-eight patients received hydrocortisone and suramin, with median suramin concentrations of 97 to 170 μg/mL for 4 weeks. No responses in measurable disease and no improvements in bone scans were seen. Five patients (18%) showed a more than 50% decline in PSA levels from baseline, of whom three had previously responded to hydrocortisone. Only two of 24 patients who did not show a posttherapy decline in PSA levels after hydrocortisone had a reduction in PSA levels with the addition of suramin. Toxicity profiles were acceptable with each agent, although a higher proportion of subjects showed hematologic, cardiac, and neurologic events when suramin was added. Conclusion: Suramin has limited efficacy in patients with androgen-independent prostate cancer who have had disease progression after hydrocortisone. |
| Keywords: | adult; clinical article; aged; clinical trial; cancer recurrence; cancer growth; drug efficacy; neurotoxicity; prospective study; prostate specific antigen; blood toxicity; hyperglycemia; prostate cancer; lung embolism; cardiotoxicity; drug blood level; flutamide; hydrocortisone; suramin; intravenous drug administration; bone scintiscanning; guillain barre syndrome; human; male; priority journal; article |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 13 |
| Issue: | 9 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 1995-09-01 |
| Start Page: | 2208 |
| End Page: | 2213 |
| Language: | English |
| DOI: | 10.1200/jco.1995.13.9.2208 |
| PUBMED: | 7545218 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 28 August 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
115Kelly -
70
Smart-Curley -
1130Scher -
78Dnistrian -
186
Schwartz
Related MSK Work